## Executive Summary

  
This report provides a comprehensive clinical, pathophysiological, and therapeutic analysis of a specific case of progressive macular dystrophy, presenting in a 34-year-old male with a 20-year history of the condition. The primary objective is to synthesize the available clinical information with the current body of scientific and medical literature to establish a definitive diagnosis, elucidate the underlying disease mechanisms, and formulate a multi-faceted strategic plan for management and future intervention.

The diagnostic analysis concludes with a high degree of confidence that the subject's condition is Best Vitelliform Macular Dystrophy (BVMD), an autosomal dominant inherited retinal disease. This conclusion is predicated on the pathognomonic clinical finding of a "very low Electrooculogram (EOG)," which is the hallmark of this disorder, in conjunction with the juvenile onset and funduscopic features consistent with the vitelliform phenotype.

The core pathophysiology of BVMD stems from mutations in the BEST1 gene, which encodes the bestrophin-1 protein. This protein forms a critical ion channel in the retinal pigment epithelium (RPE), the cell layer responsible for nourishing and maintaining the light-sensing photoreceptors. The genetic defect impairs the RPE's fundamental ability to regulate fluid and ion transport. This primary dysfunction precipitates a cascade of secondary pathological events, including the accumulation of chronic subretinal fluid and macular edema, the deposition of toxic cellular debris (lipofuscin), and subsequent progressive damage and atrophy of the macular photoreceptors. This underlying mechanism directly accounts for the subject's primary symptoms of a dense central scotoma (blind spot), profound metamorphopsia (visual distortion), and the complex photopsic phenomena described.

Based on this comprehensive analysis, a three-tiered strategic plan is recommended. Tier 1: Immediate Adaptation and Supportive Care involves the implementation of actionable strategies to mitigate symptoms and support retinal health. This includes adopting a specific nutritional supplement regimen based on the Age-Related Eye Disease Study 2 (AREDS2), targeted dietary and lifestyle modifications, and a complete optimization of the professional programming environment with specialized software, high-contrast visual themes, hyperlegible fonts, and advanced adaptive technologies such as voice-activated coding. Tier 2: Specialist Consultation and Definitive Diagnosis emphasizes the critical importance of re-engaging with specialist care at a center of excellence for inherited retinal diseases. The goals are to obtain a definitive molecular diagnosis through genetic testing for the BEST1 gene, establish a precise structural and functional baseline using advanced multimodal imaging, and discuss potential off-label medical therapies for the management of chronic subretinal fluid. Tier 3: Long-Term Horizon Scanning and Therapeutic Preparedness outlines a proactive strategy for monitoring the progression of the disease and actively tracking the development of emerging, disease-modifying treatments. The most promising of these is BEST1 gene augmentation therapy, which has shown remarkable success in preclinical models and is moving toward human clinical trials. This structured approach is designed to empower the subject with a deep understanding of his condition and a clear, actionable pathway to preserve function and prepare for future therapeutic opportunities.

  

## Diagnostic Synthesis and Pathophysiological Framework

  
  

### Establishing the Diagnosis: Best Vitelliform Macular Dystrophy (BVMD)

  

A rigorous diagnostic assessment, integrating the subject's clinical history and objective findings with established ophthalmological criteria, points conclusively to a diagnosis of Best Vitelliform Macular Dystrophy (BVMD). This conclusion is anchored by the presence of a single, pathognomonic electrophysiological sign that effectively distinguishes BVMD from other macular dystrophies with overlapping features.

The most decisive clinical marker in the subject's history is the report of a "very low Electrooculogram (EOG)." The EOG is a specialized electrophysiological test that measures the health and function of the retinal pigment epithelium (RPE) across the entire retina by recording the standing potential of the eye during dark and light adaptation. A markedly abnormal EOG, quantified by a reduced light peak to dark trough ratio (known as the Arden ratio), is the definitive hallmark of bestrophinopathies, the family of diseases caused by mutations in the BEST1 gene.1 This finding of pan-retinal RPE dysfunction is present in virtually all affected individuals at all stages of the disease, including the very early previtelliform stage where the fundus may appear entirely normal, and even in asymptomatic genetic carriers.5 The presence of this specific electrical signature is therefore of paramount diagnostic importance. While rare cases of genetically confirmed Best disease with a normal EOG have been documented, these are exceptional; a profoundly abnormal EOG is overwhelmingly indicative of the condition.7

This central finding is strongly corroborated by the broader clinical context. The onset of the condition at age 14, its initial classification as "Juvenile Macular Degeneration," and its bilateral presentation are all classic features of BVMD.1 Furthermore, the current ocular presentation, characterized by permanent central scarring and chronic subretinal fluid, is entirely consistent with the natural history of BVMD as it progresses into its advanced atrophic and exudative stages.1

The EOG finding serves as a powerful tool for differential diagnosis, allowing for the confident exclusion of other conditions that might otherwise be considered.

- Stargardt Disease: While Stargardt disease is the most common juvenile macular dystrophy, it presents a distinct clinical picture. It is typically an autosomal recessive condition caused by mutations in the ABCA4 gene. Its funduscopic appearance is characterized by yellow-white, pisciform (fish-tail shaped) flecks in the posterior pole, and while electrophysiological tests can be abnormal, a severely depressed EOG is not its defining feature.12
    
- Central Serous Chorioretinopathy (CSCR): CSCR can also cause subretinal fluid in young to middle-aged males. However, CSCR is not a progressive, degenerative dystrophy and is not associated with a pathologically low EOG. It is often linked to specific triggers like corticosteroid use or psychological stress and has characteristic leakage patterns on fluorescein angiography that differ from the findings in BVMD.14 The chronic, progressive, and scarring nature of the subject's condition is inconsistent with a diagnosis of CSCR.
    
- Adult-Onset Vitelliform Macular Dystrophy (AVMD): This condition is also a bestrophinopathy and can share a similar fundus appearance. However, as its name implies, the onset is typically between the ages of 30 and 50. Crucially, the vitelliform lesions are generally smaller than in classic BVMD, and the EOG is characteristically normal or only mildly abnormal.5 The subject's juvenile onset and severely impaired EOG are definitive discriminators.
    

The convergence of a pathognomonic electrophysiological sign with a consistent clinical history and presentation establishes the diagnosis of BVMD with a very high degree of certainty. This diagnostic clarity is essential, as it directs all further investigation toward the known genetic and cellular mechanisms of BEST1-related retinal disease.

  

### The Genetic and Cellular Basis of Disease: BEST1 and the Retinal Pigment Epithelium (RPE)

  

Best vitelliform macular dystrophy is a monogenic disorder, meaning it is caused by mutations in a single gene. The fundamental defect lies within the genetic code for a protein that is vital to the function of the retinal pigment epithelium.

The causative gene for BVMD is BEST1 (previously known as VMD2), located on the long arm of chromosome 11.5 The disease is inherited in an autosomal dominant pattern, which means that a mutation in only one of the two copies of the gene is sufficient to cause the disease.10 This inheritance pattern also means that an affected individual has a 50% probability of passing the mutation on to each of their children.9 The disease exhibits variable expressivity, meaning individuals with the same mutation can have different degrees of severity, and incomplete penetrance, where some individuals who carry the mutation may remain asymptomatic throughout their lives.5

The BEST1 gene provides the blueprint for a 585-amino acid protein called bestrophin-1.23 In the eye, this protein is expressed exclusively in the RPE.24 Structurally, five individual bestrophin-1 protein units assemble to form a stable, barrel-shaped, pentameric channel that is embedded in the cell membrane.20 This channel is specifically localized to the basolateral membrane of the RPE cells—the side that faces the choroid, the eye's primary blood supply.19

The primary function of the bestrophin-1 channel is to regulate the transport of ions, principally chloride (Cl−), across the RPE cell membrane.27 Its activity is gated by the concentration of intracellular calcium (

Ca2+); for this reason, it is classified as a calcium-activated chloride channel (CaCC).22 This regulated flow of chloride ions is a cornerstone of the RPE's complex physiological role. It is essential for driving the transepithelial transport of fluid, maintaining the delicate ionic balance of the subretinal space (the microscopic area between the RPE and the photoreceptors), and controlling the RPE cell's own volume and internal environment.20

Over 250 different disease-causing mutations in the BEST1 gene have been identified.22 These mutations lead to a "channelopathy"—a disease caused by the dysfunction of an ion channel.22 The mutation can disrupt the protein's function in several ways: it may prevent the channel from assembling correctly, stop it from being transported to the correct location on the cell membrane, or allow it to be placed correctly but prevent it from opening and closing properly.29 In dominant diseases like BVMD, the mutant protein produced from the faulty gene copy can also interfere with the function of the normal protein produced from the healthy gene copy, a phenomenon known as a dominant-negative effect.24 Regardless of the specific molecular mechanism, the result is a failure of the RPE's ion and fluid transport machinery, which is the primary pathological event that initiates the entire disease cascade.27

  

### The Cascade of Retinal Degeneration

  

The primary genetic defect in the BEST1 gene sets off a predictable, albeit slow, cascade of events within the retina, beginning with RPE dysfunction and culminating in the loss of central vision. This progression from a microscopic channelopathy to macroscopic structural damage explains the full spectrum of the disease.

The initial and most direct consequence of the faulty bestrophin-1 channel is the disruption of the RPE's fluid-pumping mechanism.20 A key function of the healthy RPE is to actively transport fluid from the subretinal space into the choroidal circulation, thereby keeping the photoreceptors tightly apposed to their support layer. This process is osmotically driven by the transport of ions, particularly chloride, through channels like bestrophin-1. When this ion transport is impaired, the pumping mechanism fails, and fluid that naturally leaks from the choroidal blood vessels is no longer efficiently removed. This fluid begins to accumulate in the subretinal space, physically separating the neurosensory retina from the RPE.25 This accumulation of subretinal fluid (SRF) is the direct cause of the macular edema and the sensation of "high fluid pressure" reported by the subject.

Concurrently, another critical function of the RPE becomes compromised: the daily phagocytosis of shed photoreceptor outer segments (POS).5 Photoreceptors constantly renew their light-sensing outer segments, shedding the oldest tips, which are then cleared by the RPE. The overall dysfunction of the RPE in BVMD impairs this vital housekeeping process.20 The result is the accumulation of undigested POS debris and its toxic, oxidized breakdown product, lipofuscin, in the subretinal space.5 This heterogeneous material is brilliantly autofluorescent and is what forms the yellow, elevated, "egg-yolk" vitelliform lesion that gives the disease its name.5

The final stage in this degenerative cascade is the damage and death of the photoreceptor cells themselves. Photoreceptors are among the most metabolically active cells in the body and are entirely dependent on the adjacent RPE for nutrient delivery, waste removal, and structural support. The combination of physical separation from the RPE by SRF, immersion in a toxic environment of lipofuscin and cellular debris, and the RPE's inability to provide adequate metabolic support creates an untenable situation for the photoreceptors.5 Over time, these stressed cells begin to malfunction and eventually undergo apoptosis (programmed cell death). This progressive loss of photoreceptors in the macula leads to the formation of permanent atrophic scars and is the ultimate cause of irreversible central vision loss in the advanced stages of BVMD.

  

## Clinical Correlation: Deconstructing the Visual Experience

  
  

### Mapping a 20-Year Journey: The Natural History of BVMD

  

The progression of Best vitelliform macular dystrophy is classically described in a series of clinical stages, providing a valuable framework for interpreting an individual's disease trajectory. While the progression is highly variable and not all patients pass through each stage in a linear fashion, this model helps to contextualize the subject's 20-year history and current clinical status.1

- Stage 1 (Previtelliform): In early childhood, prior to the diagnosis at age 14, the subject's eyes were likely in this stage, characterized by a normal fundus appearance but a subclinically abnormal EOG.5
    
- Stage 2 (Vitelliform): The diagnosis at age 14 likely coincided with the appearance of the classic, well-defined, yellow "egg-yolk" lesion in the macula. Despite the dramatic funduscopic appearance of this stage, central visual acuity is often remarkably preserved, typically in the range of 20/20 to 20/60, which aligns with the subject's ability to function without significant impairment for many years.5
    
- Stage 3 (Pseudohypopyon): This stage, often occurring during puberty and the teenage years, involves the partial liquefaction of the vitelliform material, which then layers out with gravity, creating a fluid level within the lesion.1 Vision typically remains good during this phase.
    
- Stage 4 (Vitelliruptive): As the uniform vitelliform material continues to break down, it takes on a heterogeneous, "scrambled-egg" appearance. It is at this stage that visual acuity typically begins to deteriorate more noticeably.5 This phase likely corresponds to the period of the subject's late teens and twenties, during which the central distortion would have become more functionally significant.
    
- Stage 5 (Atrophic): In this advanced stage, the vitelliform material is largely reabsorbed by the RPE, leaving behind a well-demarcated area of chorioretinal atrophy—a permanent scar where the RPE and photoreceptors have been lost. This stage is associated with marked and permanent loss of central vision and typically occurs after the age of 40, though it can manifest earlier.1
    
- Stage 6 (Cicatricial/Choroidal Neovascularization - CNV): This is a late-stage complication where abnormal, fragile blood vessels grow from the choroid into the subretinal space. These vessels can leak fluid and blood, leading to rapid visual decline and the formation of a fibrous subretinal scar. CNV occurs in approximately 20% of individuals with Best disease and represents a significant threat to remaining vision.1
    

At 34 years of age, the subject's clinical picture—described as permanent central scarring compounded by chronic subretinal fluid and macular edema—represents a complex and advanced phenotype. He appears to be in a hybrid state that combines the irreversible damage of the atrophic stage with the ongoing exudative processes (fluid leakage) that characterize the earlier stages. This persistent fluid accumulation is a key feature of his dynamic symptomatology and may also represent an environment conducive to the future development of CNV. The overall slow progression of his condition over two decades is consistent with large natural history studies, which have found an average rate of visual deterioration of less than one ETDRS letter per year in BVMD cohorts.19

  

### The Pathophysiology of Perception

  

The subject's unique and dynamic visual experience can be directly mapped to specific physiological and neurological consequences of his underlying retinal pathology. The scotoma, metamorphopsia, and complex photopsia are not disparate symptoms but rather an interconnected cascade of events occurring at the retinal and cortical levels.

  

#### Metamorphopsia and the Central Scotoma

  

The profound warping of straight lines (metamorphopsia) and the central area of fuzziness or blindness (scotoma) are direct perceptual manifestations of the structural damage in the macula. Metamorphopsia arises from the physical displacement of the photoreceptor cells from their normal, highly ordered mosaic.39 The chronic subretinal fluid lifts the retina, creating elevation and separation, while the underlying atrophic scarring results in an irregular, uneven surface. When light enters the eye, it is no longer focused onto a smooth, correctly aligned grid of photoreceptors. The brain receives spatially jumbled signals from these displaced photoreceptors and, in its attempt to construct a coherent image, interprets straight lines in the external world as curved or wavy.12 The central scotoma corresponds to those areas of the macula where the photoreceptors have been permanently lost due to the atrophic process, creating an absolute blind spot in the visual field.3

  

#### Understanding Symptom Fluctuation

  

The significant day-to-day variability in the severity of visual distortion is a critical aspect of the subject's experience and points to a dynamic component of the pathology, superimposed on the fixed, permanent scarring. This fluctuation is almost certainly driven by changes in the volume and pressure of the subretinal fluid and macular edema.43 While the fundamental RPE defect is constant, the rate of fluid leakage into the subretinal space is not.

Although the specific triggers for fluid fluctuation in BVMD are not well-studied, a powerful and relevant model can be drawn from Central Serous Chorioretinopathy (CSCR), another condition defined by subretinal fluid. In CSCR, there is overwhelming evidence linking psychological stress and elevated levels of systemic corticosteroids (including endogenous cortisol) to increased permeability of the choroidal vasculature, which drives fluid leakage across a compromised RPE.16 Cortisol, the body's primary stress hormone, follows a natural diurnal rhythm, typically peaking in the morning after waking. It is highly plausible that a similar mechanism influences the fluid dynamics in BVMD. The genetically compromised RPE in Best disease is likely more vulnerable to systemic physiological changes. Therefore, daily variations in stress levels, blood pressure, and circadian hormonal fluctuations could modulate choroidal blood flow and permeability, leading to changes in the amount of subretinal fluid. This provides a compelling physiological explanation for the subject's experience of having "good days" and "bad days," and why his vision might be clearer upon waking (after a period of physical rest and potentially lower cortisol levels) and worsen throughout a demanding and stressful workday.

  

#### Decoding Complex Photopsia: "Fractal Shapes and Colors"

  

The description of the central visual disturbance containing "abstract with fractal shapes and colors" is a classic account of a neurological phenomenon known as a cortical release hallucination. This is not a direct symptom of the retinal disease itself but rather the brain's creative response to the lack of sensory input. This phenomenon is the basis of Charles Bonnet Syndrome (CBS), which affects cognitively normal individuals who have experienced significant vision loss.48

The mechanism is understood as a "release phenomenon".48 The visual cortex in the brain is constantly active, processing a steady stream of information from the eyes. When a portion of the retina, such as the macula, is damaged and can no longer send signals, the corresponding area of the visual cortex is deprived of its normal input. This deafferentation leads to a state of hyperexcitability, and the cortical neurons begin to fire spontaneously, generating their own perceptions to "fill in" the missing data from the scotoma. These internally generated images can range from simple flashes of light (phosphenes) and geometric patterns to extremely complex and vivid scenes. The subject's description of intricate, colorful, and fractal-like shapes is a well-documented form of these complex, non-psychiatric visual hallucinations.52 Understanding this phenomenon is crucial, as it demystifies a potentially alarming symptom, correctly attributing it to a predictable neurological adaptation to sensory loss rather than a sign of a primary brain or psychiatric disorder.

This integrated model of perception demonstrates how the subject's three primary symptoms are causally linked. The permanent retinal damage creates the scotoma; the dynamic fluid component overlying this damage physically displaces the remaining photoreceptors, causing the fluctuating metamorphopsia; and the brain's response to the information void of the scotoma generates the complex photopsia. This understanding is not merely academic; it validates the subject's experience and suggests that management strategies targeting systemic factors, such as stress, may have a tangible effect on daily visual function.

  

## Therapeutic and Management Strategies: Established and Supportive Interventions

  
  

### Addressing Chronic Subretinal Fluid and Macular Edema

  

The management of chronic subretinal fluid (SRF) that is a primary manifestation of BVMD presents a significant clinical challenge, as there are currently no standard, approved treatments to address this specific aspect of the disease.2 The historical suggestion of an invasive procedure to manually extract the fluid via a needle is not a contemporary standard of care, primarily due to its high risk, transient effect, and potential to cause further retinal damage. Consequently, management is often limited to observation and monitoring for secondary complications.

However, the understanding of SRF pathophysiology in related conditions offers potential avenues for off-label therapeutic exploration. A compelling parallel exists with Central Serous Chorioretinopathy (CSCR), where dysregulation of the mineralocorticoid receptor (MR) pathway in the choroid is strongly implicated in promoting vascular leakage and fluid accumulation.16 Clinical studies in CSCR have demonstrated that systemic administration of MR antagonists, such as spironolactone and eplerenone, can be effective in reducing SRF and improving visual outcomes.54 Given the shared final common pathway of fluid accumulation under the retina, there is a strong scientific rationale to consider the off-label use of these oral medications for the persistent, chronic SRF seen in advanced BVMD. This represents a tangible, non-invasive pharmacological strategy that warrants a detailed discussion with a retinal specialist who has expertise in both inherited retinal diseases and the pachychoroid spectrum of disorders. Preclinical research is also underway to develop localized delivery methods, such as intravitreal microspheres, to maximize therapeutic effect in the eye while minimizing potential systemic side effects.54

  

### Management of Choroidal Neovascularization (CNV)

  

Choroidal neovascularization is a serious, sight-threatening complication that can arise in the advanced stages of BVMD, affecting up to 20% of patients.1 It involves the pathological growth of new blood vessels from the choroid through Bruch's membrane and into the subretinal space. These vessels are fragile and prone to leaking fluid and blood, which can cause rapid and severe vision loss and lead to the formation of a disciform fibrous scar.5

Proactive and vigilant monitoring is the cornerstone of managing this risk. Regular self-monitoring with an Amsler grid to detect any new or worsening distortion, coupled with periodic clinical examinations including Optical Coherence Tomography (OCT), is essential for early detection.

Should CNV develop, the definitive standard of care is intravitreal therapy with anti-vascular endothelial growth factor (anti-VEGF) agents.7 VEGF is a key signaling protein that promotes the growth of abnormal blood vessels. Anti-VEGF medications are antibodies or antibody fragments that bind to and neutralize VEGF, thereby causing the abnormal vessels to regress and the leakage to resolve.

- Available Agents: The most commonly used anti-VEGF agents are ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin).56
    
- Efficacy in BVMD: Clinical trials and case series have demonstrated that anti-VEGF therapy is beneficial for treating CNV secondary to BVMD. Treatment can lead to the resolution of fluid, regression of the neovascular membrane, and stabilization or improvement of visual acuity.57 In a study involving adolescents with CNV from various causes, including two with Best disease, treatment with ranibizumab resulted in significant mean gains in visual acuity and reductions in central retinal thickness over 12 months, requiring an average of only three injections.60 However, it is important to note that the response can be variable, and some cases may prove to be persistent or resistant to treatment, requiring a switch in agent or more frequent injections.55
    

Legacy treatments such as photodynamic therapy (PDT) with verteporfin or focal laser photocoagulation were previously used for CNV but have been largely supplanted by the superior efficacy and safety profile of anti-VEGF agents.2 Anti-VEGF therapy remains the first-line treatment for this complication.

  

### Nutritional and Lifestyle Interventions for Retinal Support

  

While there are no clinical trials specifically evaluating nutritional interventions for Best vitelliform macular dystrophy, the disease's core pathophysiology involves RPE dysfunction and heightened oxidative stress, which are also central to the pathogenesis of Age-Related Macular Degeneration (AMD).63 Therefore, the robust evidence from the large-scale Age-Related Eye Disease Studies (AREDS and AREDS2) provides the most scientifically grounded guidance for supportive nutritional care in BVMD.

The AREDS2 trial established that a specific high-dose oral supplement containing antioxidants and minerals can significantly slow the progression from intermediate to advanced AMD.65 Given the shared pathological mechanisms, it is a reasonable and low-risk strategy to adopt this formulation to provide maximal nutritional support to the stressed RPE cells in BVMD.

Table 1: AREDS2 Formulation and Key Nutrient Sources

|   |   |   |
|---|---|---|
|Nutrient|AREDS2 Daily Dose|Rich Dietary Sources|
|Vitamin C|500 mg|Citrus fruits (oranges, grapefruit), bell peppers, strawberries, broccoli, kiwi|
|Vitamin E|400 IU|Nuts (almonds, hazelnuts), seeds (sunflower seeds), spinach, vegetable oils|
|Lutein|10 mg|Leafy greens (kale, spinach), corn, egg yolks, zucchini, broccoli|
|Zeaxanthin|2 mg|Leafy greens (kale, spinach), corn, bell peppers (orange/yellow), goji berries|
|Zinc (as zinc oxide)|80 mg|Oysters, red meat, poultry, beans, nuts, whole grains|
|Copper (as cupric oxide)|2 mg|Shellfish, whole grains, beans, nuts, potatoes, organ meats|

Note: Copper is included in the formula to prevent copper-deficiency anemia, a potential side effect of high-dose zinc supplementation. 67

In addition to supplementation, a diet that is naturally rich in these nutrients is strongly recommended. A Mediterranean-style diet, characterized by high intake of fruits, vegetables, legumes, whole grains, fish, and nuts, has been associated with a reduced risk of AMD progression.68 A high intake of omega-3 fatty acids, particularly DHA and EPA found in oily fish like salmon, mackerel, and sardines, is also believed to be beneficial for retinal health, although the AREDS2 trial did not find an additional benefit from adding them to the supplement formula.65

Lifestyle modifications are equally critical for minimizing additional stress on the retina:

- Smoking Cessation: Smoking is the most significant modifiable environmental risk factor for macular degeneration. It dramatically increases oxidative stress and inflammation, accelerating disease progression. Complete avoidance of smoking is imperative.64
    
- UV and Blue Light Protection: Chronic exposure to high-energy visible (blue) light and ultraviolet (UV) radiation is believed to contribute to photochemical damage and oxidative stress in the RPE.71 While the evidence for the benefit of blue-light filtering lenses in preventing disease progression remains inconclusive, the use of high-quality sunglasses that provide 100% protection against UVA and UVB radiation when outdoors is a strongly recommended and prudent protective measure.74
    

  

## Horizon Scanning: The Future of Treatment

  

The therapeutic landscape for inherited retinal diseases is undergoing a revolutionary transformation, moving from supportive care to targeted, disease-modifying interventions. For individuals with BVMD, several promising avenues of research, particularly gene therapy and stem cell therapy, offer the potential to address the root cause of the disease in the future.

  

### Gene Therapy: Correcting the Foundational Defect

  

Gene therapy represents the most direct and promising future treatment for BVMD. The strategy, known as gene augmentation, aims to deliver a healthy, functional copy of the BEST1 gene directly to the affected RPE cells.24 The introduction of this correct genetic blueprint allows the cells to produce normal bestrophin-1 protein, with the goal of restoring proper ion channel function and halting the degenerative cascade.

The delivery vehicle of choice for retinal gene therapy is a non-pathogenic, bio-engineered adeno-associated virus (AAV). The AAV vector is loaded with the therapeutic BEST1 gene and administered via a single subretinal injection, a surgical procedure that places the vector in direct contact with the target RPE cells.24

The preclinical evidence for this approach is exceptionally strong. Extensive research conducted in a naturally occurring canine model of bestrophinopathy, which closely mimics the human disease, has demonstrated remarkable success. A single subretinal injection of an AAV vector carrying the BEST1 gene was shown to correct the underlying cellular pathology, restore the proper interface between the RPE and photoreceptors, and, most impressively, lead to the complete resolution of established, large vitelliform lesions.27 This powerful proof-of-concept in a large animal model provides a solid foundation for translation to human clinical trials.

Despite this promising data, there are currently no active, recruiting clinical trials for BEST1 gene therapy in the United Kingdom or elsewhere, as of the latest available information.78 However, the field is advancing at a rapid pace. The landmark regulatory approval of Luxturna, a gene therapy for a different inherited retinal disease caused by

RPE65 mutations, has paved the way and accelerated the development pipeline for other conditions.24 Several biotechnology companies and academic centers are actively pursuing

BEST1 gene therapy programs at the preclinical and IND (Investigational New Drug)-enabling stages.24

The slow natural progression of BVMD presents a unique challenge for clinical trial design. While this slow decline provides a long therapeutic window where retinal cells remain viable and amenable to rescue, it also makes it difficult to demonstrate a statistically significant therapeutic benefit over the typical 1- to 2-year duration of a clinical trial. Proving that a treatment has slowed a decline of less than one visual acuity letter per year is challenging. Consequently, future trials will likely rely on more sensitive, objective outcome measures, such as changes in SRF volume on OCT, retinal sensitivity measured by microperimetry, or fundus autofluorescence patterns, to demonstrate efficacy.21

  

### Cellular Regeneration: The Promise of Stem Cell Therapy

  

For advanced stages of BVMD where significant RPE and photoreceptor cell death has already occurred, gene therapy may be less effective. In these cases, stem cell therapy offers a potential regenerative strategy. The goal is to replace the lost, dysfunctional RPE cells with new, healthy ones grown in a laboratory.84

The most promising approach involves the use of induced pluripotent stem cells (iPSCs). This technology allows scientists to take a small sample of a patient's own somatic cells, such as skin or blood cells, and reprogram them into a stem-cell-like state. These iPSCs can then be directed to differentiate into any cell type in the body, including RPE cells.84 For a genetic disease like BVMD, an additional step would be required: using a gene-editing tool like CRISPR/Cas9 to correct the

BEST1 mutation in the patient's iPSCs before they are differentiated into RPE cells. These genetically corrected, patient-specific RPE cells could then be transplanted as a cell suspension or as a structured monolayer sheet into the subretinal space, theoretically restoring a healthy RPE layer without the risk of immune rejection.

The field of stem cell therapy for retinal diseases is advancing rapidly, with several Phase I/II clinical trials currently underway for dry AMD and Stargardt disease.85 These early-stage trials are primarily focused on establishing the safety and feasibility of the transplantation procedure. While some encouraging results have been reported, including the survival of transplanted cells and modest improvements in vision in some participants, the technology remains in the early stages of clinical development.84

  

### Neuroprosthetics and Artificial Vision

  

In the theoretical end-stage of the disease, characterized by profound and widespread loss of photoreceptors, neuroprosthetic retinal implants represent a potential future option for vision restoration. Devices such as the Argus II system function by bypassing the degenerated photoreceptors entirely. An external camera mounted on a pair of glasses captures the visual scene, which is then converted into electrical signals and transmitted to an electrode array surgically implanted on the surface of the retina. These electrodes directly stimulate the surviving inner retinal neurons (ganglion cells), which then send signals to the brain, creating an artificial form of vision composed of patterns of light spots called phosphenes.88

Currently, this technology is highly experimental and provides only rudimentary, low-resolution vision, enabling tasks like light perception and the detection of large, high-contrast shapes.89 It is reserved for individuals with profound blindness and is not relevant to the subject's current functional status, but it represents an area of active research for the most advanced forms of retinal degeneration.91

  

## Professional Adaptation: A High-Performance Toolkit for the Visually Impaired Programmer

  

Maintaining a high level of productivity in a visually intensive profession such as programming requires a strategic and personalized approach to workplace adaptation. The goal is to move beyond basic accessibility features and cultivate a high-performance digital environment that minimizes visual strain, maximizes efficiency, and leverages powerful, discreet assistive technologies. This toolkit is designed to be implemented immediately to provide tangible benefits to the subject's daily workflow.

  

### Optimizing the Digital Workspace: The Foundation

  

The Integrated Development Environment (IDE) is the programmer's primary workspace, and its customization is the first and most critical step in creating a sustainable and comfortable coding environment.

  

#### IDE Configuration for Visual Clarity

  

- High-Contrast Themes: The human visual system detects objects based on luminance contrast. For individuals with macular dystrophy, maximizing the contrast between text and background is essential for reducing eye strain and improving character recognition. Most modern IDEs, including Visual Studio Code, the JetBrains suite (IntelliJ IDEA, PyCharm, etc.), and Sublime Text, offer a wide array of built-in and community-developed high-contrast themes.93 Recommended themes to explore include the default "High Contrast" themes available in most editors, as well as popular dark themes like "Night Owl," which is specifically designed for readability in low-light conditions, and "Dracula Official," known for its carefully selected, vibrant but not jarring, color palette.95 The choice is highly personal, and experimentation is key. For JetBrains IDEs, the "High Contrast" theme can be activated in the settings, and every element of the color scheme can be manually customized for optimal comfort.94
    
- Hyperlegible and Monospaced Fonts: Font selection is paramount for code legibility. A monospaced font, where every character occupies the same horizontal width, is non-negotiable for maintaining code alignment and structure. For low vision, the font's design must prioritize "hyperlegibility"—the unambiguous differentiation of similar characters. Characters such as '1', 'l', and 'I', or '0' and 'O', must be instantly distinguishable to prevent syntax errors and reduce cognitive load.99 An exceptional and highly recommended choice is the  
    Atkinson Hyperlegible Mono™ font, developed by the Braille Institute. It was specifically engineered for readers with low vision and is available for free for all uses, including commercial. Its design principles focus on maximizing character distinctiveness, making it an ideal font for a coding environment.99 Other well-regarded fonts include Fira Code, which features programming ligatures (e.g., combining  
    -> into a single arrow glyph), and Verdana, known for its generous spacing.101
    
- Cursor and Text Customization: To avoid losing track of the insertion point within a sea of code, the text cursor should be made highly visible. Most IDEs allow for customization of the cursor's style (e.g., block, line, underline), thickness, and blink rate.102 A thick, non-blinking block cursor is often most effective. Additionally, increasing the line height (  
    line-spacing) and letter spacing can significantly reduce visual clutter and improve the ability to track lines of code, especially for those with central field defects.100
    

  

#### Integrating Auditory Feedback

  

- Advanced Screen Readers as Assistants: Modern screen readers like JAWS and the open-source NVDA can be powerful tools for sighted programmers with low vision, serving not as a primary interface but as a targeted auditory assistant.104 Instead of reading the entire screen, they can be configured with keyboard shortcuts to read the current line, the current function definition, a specific variable, or syntax errors. This allows for rapid, "eyes-off" verification of code, reducing the need to constantly scan the screen and mitigating visual fatigue. The effectiveness of these tools in web-based developer environments depends heavily on the use of proper semantic HTML and ARIA (Accessible Rich Internet Applications) attributes by the web application developers.106
    
- High-Fidelity Screen Magnifiers: While operating systems have built-in magnifiers, dedicated software such as ZoomText (often available in a combined package with JAWS called Fusion) offers superior functionality. Features like xFont technology for smooth text rendering at high magnification, enhanced cursor and pointer visibility options, and customizable color filtering can provide a significantly better user experience than basic OS tools.105
    

  

### Advanced and Discreet Adaptive Technologies

  

Beyond optimizing the existing environment, leveraging cutting-edge, hands-free technologies can provide a transformative shift in workflow, enhancing productivity while preserving visual stamina.

  

#### Voice-Activated Coding with Talon Voice

  

Talon Voice is a sophisticated, open-source platform for controlling a computer and writing code entirely by voice.110 It is crucial to understand that Talon is not a simple dictation program; it is a programmable command-and-control system that allows for highly efficient, structured input.

- Functionality: Users interact with Talon using a defined phonetic alphabet (e.g., "air" for 'a', "bat" for 'b') and a grammar of commands to write code, execute shortcuts, navigate applications, and control the mouse pointer.111 The entire system is extensible and customizable using Python scripts, making it exceptionally powerful for a developer.112
    
- Relevance and Discretion: For a programmer experiencing visual distortion and fatigue, Talon offers a paradigm-shifting advantage. It enables periods of "heads-up" or "eyes-off" coding, where complex logic can be dictated without intense visual focus on the screen. This dramatically reduces visual strain over a long workday. Furthermore, the system is entirely discreet, requiring only a high-quality microphone and running silently in the background. The extensive community-developed script repository on GitHub provides pre-built, robust command sets for most major programming languages, including Python, JavaScript, and C++, as well as integrations for version control (Git) and popular IDEs.111 Investing the time to learn Talon could be the single most impactful adaptation for ensuring long-term professional productivity.
    

  

#### Novel Reading Aids

  

- Bionic Reading: This is a novel reading methodology that bolds the initial few letters of each word, creating artificial fixation points. The theory is that this guides the reader's eyes through the text more efficiently, allowing the brain to complete the words and thereby increasing reading speed and reducing cognitive load.116 While primarily designed for prose, its potential application to code is intriguing. Various browser extensions and apps exist, and the availability of an API suggests that a custom script or IDE plugin could be developed to apply this transformation to code within an editor, potentially aiding in the rapid scanning of dense source files.116
    

  

### Future of Visual Augmentation

  

Emerging research is exploring the possibility of digitally correcting metamorphopsia in real-time. Technologies like the Image Warping Test (IWT) can create a precise digital map of a patient's unique visual distortion.120 The logical next step, though still in the research phase, is to use this map to apply an inverse-warp transformation to a live video feed. This corrected feed could then be displayed on a "see-through" head-mounted display (a form of augmented reality). While this technology is not yet commercially available, it represents a significant area of future development that could one day offer a non-invasive means of neutralizing the most debilitating visual symptoms of macular disease.

  

## Synthesis and Strategic Recommendations

  

This comprehensive analysis culminates in a multi-tiered, actionable strategic plan designed to address the subject's immediate needs, establish a foundation for expert long-term care, and prepare for future therapeutic innovations. The recommendations are structured to be implemented sequentially, providing a clear and logical path forward.

  

### Immediate Actions (Self-Management and Optimization)

  

These are proactive steps that can be implemented immediately to support retinal health and optimize professional function.

- Initiate Nutritional Protocol: Begin daily supplementation with a commercially available Age-Related Eye Disease Study 2 (AREDS2) formula. This is the most evidence-based nutritional intervention for supporting RPE health in macular degenerative conditions. Concurrently, adopt a Mediterranean-style diet, focusing on increasing intake of dark leafy greens (kale, spinach), colorful fruits and vegetables, and omega-3-rich fatty fish (e.g., salmon, mackerel) to at least two servings per week.
    
- Implement Lifestyle Modifications: Ensure consistent use of high-quality, 100% UV-blocking sunglasses for all outdoor activities. Complete cessation of smoking, if applicable, is the single most impactful lifestyle change to reduce oxidative stress on the retina.
    
- Explore Systemic Factor Management: Given the plausible link between systemic stress and fluctuations in subretinal fluid, actively incorporate stress management techniques into the daily routine. This could include mindfulness practices, meditation, or regular physical exercise. Ensure routine monitoring and management of systemic blood pressure.
    
- Execute Professional Workspace Overhaul: Systematically implement the adaptations detailed in Section VI. This includes installing and experimenting with high-contrast IDE themes and hyperlegible monospaced fonts like Atkinson Hyperlegible Mono. Customize cursor and text settings for maximum visibility. Critically, begin the process of learning and integrating Talon Voice into the workflow; its potential to reduce visual strain and preserve long-term productivity is immense.
    

  

### Consultative Actions (Engaging with Specialist Care)

  

The 20-year gap in specialist follow-up is a critical issue that must be rectified to ensure access to modern diagnostics, expert management, and future treatments.

- Seek Referral to a Specialist Inherited Retinal Disease (IRD) Center: The primary recommendation is to obtain a referral from a General Practitioner or private ophthalmologist to a national center of excellence for IRDs in the United Kingdom. The Genetics Service at Moorfields Eye Hospital in London is a world-leading institution for the diagnosis and management of these conditions and would be an ideal choice.121
    
- Objectives for Specialist Consultation:
    

1. Definitive Molecular Diagnosis: The foremost goal is to undergo genetic testing with a comprehensive IRD gene panel to identify the specific causative mutation in the BEST1 gene. This molecular confirmation is no longer merely academic; it is becoming an essential prerequisite for eligibility in gene-specific clinical trials.122
    
2. Advanced Multimodal Imaging: A complete diagnostic workup should be performed to establish a robust baseline. This includes spectral-domain optical coherence tomography (SD-OCT) to precisely map and quantify retinal thickness, subretinal fluid, and areas of atrophy; fundus autofluorescence (FAF) to assess the health and distribution of lipofuscin in the RPE; and OCT angiography (OCT-A) to definitively rule out the presence of a choroidal neovascular membrane.24
    
3. Establishment of a Clinical Baseline: This comprehensive evaluation will provide a precise, quantitative baseline of the disease's current state. This is invaluable for accurately tracking future progression and is a critical requirement for enrollment in most clinical trials.
    
4. Discussion of Therapeutic Options: This consultation provides the opportunity for an expert-level discussion regarding current management. This should include exploring the potential risks and benefits of an off-label trial of mineralocorticoid receptor antagonists (e.g., spironolactone) for the management of chronic subretinal fluid, and establishing a clear, proactive plan for monitoring and treating potential CNV with anti-VEGF therapy.
    

  

### Long-Term Strategy (Proactive Future-Proofing)

  

This involves adopting a forward-looking mindset focused on actively monitoring and preparing for the next generation of therapies.

- Clinical Trial Monitoring: By establishing a relationship with a specialist IRD center, the subject will be ideally positioned to receive information about and be considered for future clinical trials. It is also advisable to periodically search clinical trial registries (e.g., ClinicalTrials.gov, the EU Clinical Trials Register) for studies related to "Best disease," "vitelliform macular dystrophy," or "BEST1."
    
- Continued Education and Advocacy: Stay informed about the progress of retinal disease research through reputable patient advocacy and research organizations such as Retina UK and Fight for Sight, and by following updates from major research bodies like the National Institute for Health and Care Research (NIHR).82 This proactive engagement will ensure readiness to act when new therapeutic opportunities emerge.
    

#### Works cited

1. Best's Vitelliform Macular Dystrophy - PMC - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5035264/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5035264/)
    
2. Best's vitelliform dystrophy - PubMed, accessed July 27, 2025, [https://pubmed.ncbi.nlm.nih.gov/2190134/](https://pubmed.ncbi.nlm.nih.gov/2190134/)
    
3. Recognizing Best's Disease - Review of Optometry, accessed July 27, 2025, [https://www.reviewofoptometry.com/article/recognizing-bests-disease](https://www.reviewofoptometry.com/article/recognizing-bests-disease)
    
4. The electro-oculogram | Request PDF - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/7303612_The_electro-oculogram](https://www.researchgate.net/publication/7303612_The_electro-oculogram)
    
5. Best Disease - StatPearls - NCBI Bookshelf, accessed July 27, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK537290/](https://www.ncbi.nlm.nih.gov/books/NBK537290/)
    
6. EyeRounds.org: Best Vitelliform Macular Dystrophy (Best Disease), accessed July 27, 2025, [https://webeye.ophth.uiowa.edu/eyeforum/cases/case11.htm](https://webeye.ophth.uiowa.edu/eyeforum/cases/case11.htm)
    
7. Normal electro-oculography in a young Omani male with genetically confirmed best disease complicated by choroidal neovascularization - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6380146/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6380146/)
    
8. A normal electro-oculography in a family affected by best disease with a novel spontaneous mutation of the BEST1 gene | Request PDF - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/23171249_A_normal_electro-oculography_in_a_family_affected_by_best_disease_with_a_novel_spontaneous_mutation_of_the_BEST1_gene](https://www.researchgate.net/publication/23171249_A_normal_electro-oculography_in_a_family_affected_by_best_disease_with_a_novel_spontaneous_mutation_of_the_BEST1_gene)
    
9. Best disease | EBSCO Research Starters, accessed July 27, 2025, [https://www.ebsco.com/research-starters/health-and-medicine/best-disease](https://www.ebsco.com/research-starters/health-and-medicine/best-disease)
    
10. An Overview of Best Disease - | International Journal of Innovative Science and Research Technology, accessed July 27, 2025, [https://www.ijisrt.com/assets/upload/files/IJISRT24MAY505.pdf](https://www.ijisrt.com/assets/upload/files/IJISRT24MAY505.pdf)
    
11. Clinical Correlation Between Optical Coherence Tomography Biomarkers and Retinal Sensitivity in Best Vitelliform Macular Dystrophy | TVST, accessed July 27, 2025, [https://tvst.arvojournals.org/article.aspx?articleid=2783677](https://tvst.arvojournals.org/article.aspx?articleid=2783677)
    
12. Best Disease (Vitelliform Macular Dystrophy): Stages & Symptoms - Cleveland Clinic, accessed July 27, 2025, [https://my.clevelandclinic.org/health/diseases/24132-best-disease](https://my.clevelandclinic.org/health/diseases/24132-best-disease)
    
13. Electrophysiological Evaluation of Macular Dystrophies - PMC - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9962076/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9962076/)
    
14. Central Serous Chorioretinopathy - EyeWiki, accessed July 27, 2025, [https://eyewiki.org/Central_Serous_Chorioretinopathy](https://eyewiki.org/Central_Serous_Chorioretinopathy)
    
15. Wet AMD Look-alikes - American Academy of Ophthalmology, accessed July 27, 2025, [https://www.aao.org/eyenet/article/wet-amd-lookalikes](https://www.aao.org/eyenet/article/wet-amd-lookalikes)
    
16. Central Serous Chorioretinopathy - StatPearls - NCBI Bookshelf, accessed July 27, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK558973/](https://www.ncbi.nlm.nih.gov/books/NBK558973/)
    
17. Vitelliform dystrophies: Prevalence in Olmsted County, Minnesota, United States - PMC, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5638045/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5638045/)
    
18. Adult-Onset Vitelliform Macular Dystrophy caused by BEST1 p.Ile38Ser Mutation is a Mild Form of Best Vitelliform Macular Dystrophy - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5567297/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5567297/)
    
19. Best Vitelliform Macular Dystrophy Natural History Study Report 1: Clinical Features and Genetic Findings, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11932931/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11932931/)
    
20. New Evidence on BEST1 Genetic Variant Identified in a Patient with Best Vitelliform Macular Dystrophy Phenotype - Austin Publishing Group, accessed July 27, 2025, [https://austinpublishinggroup.com/ophthalmology-visual-sciences/fulltext/jovs-v6-id1054.php](https://austinpublishinggroup.com/ophthalmology-visual-sciences/fulltext/jovs-v6-id1054.php)
    
21. Fixation Location and Stability in Best Vitelliform Macular Dystrophy - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10251068/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10251068/)
    
22. Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 ..., accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7934022/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7934022/)
    
23. A Homozygous Frameshift Mutation in BEST1 Causes the Classical Form of Best Disease in an Autosomal Recessive Mode | IOVS, accessed July 27, 2025, [https://iovs.arvojournals.org/article.aspx?articleid=2187627](https://iovs.arvojournals.org/article.aspx?articleid=2187627)
    
24. Gene therapy in bestrophinopathies: Insights from preclinical studies ..., accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10752275/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10752275/)
    
25. The spectrum of ocular phenotypes caused by mutations in the BEST1 gene - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/24306617_The_spectrum_of_ocular_phenotypes_caused_by_mutations_in_the_BEST1_gene](https://www.researchgate.net/publication/24306617_The_spectrum_of_ocular_phenotypes_caused_by_mutations_in_the_BEST1_gene)
    
26. Distinct expression requirements and rescue strategies for BEST1 loss- and gain-of-function mutations | eLife, accessed July 27, 2025, [https://elifesciences.org/articles/67622](https://elifesciences.org/articles/67622)
    
27. BEST1 gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure | PNAS, accessed July 27, 2025, [https://www.pnas.org/doi/10.1073/pnas.1720662115](https://www.pnas.org/doi/10.1073/pnas.1720662115)
    
28. Disease expression caused by different variants in the BEST1 gene: genotype and phenotype findings in bestrophinopathies - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9328113/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9328113/)
    
29. Best Disease and Bestrophinopathies - EyeWiki, accessed July 27, 2025, [https://eyewiki.org/Best_Disease_and_Bestrophinopathies](https://eyewiki.org/Best_Disease_and_Bestrophinopathies)
    
30. (PDF) Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 function and developing therapies - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/349671981_Bestrophinopathies_perspectives_on_clinical_disease_Bestrophin-1_function_and_developing_therapies](https://www.researchgate.net/publication/349671981_Bestrophinopathies_perspectives_on_clinical_disease_Bestrophin-1_function_and_developing_therapies)
    
31. Patient-specific mutations impair BESTROPHIN1's essential role in ..., accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5655127/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5655127/)
    
32. Functional Roles of Bestrophins in Ocular Epithelia - PMC, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC2740978/](https://pmc.ncbi.nlm.nih.gov/articles/PMC2740978/)
    
33. Human BEST1 mutations cause defective fluid transport in RPE and... | Download Scientific Diagram - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/figure/Human-BEST1-mutations-cause-defective-fluid-transport-in-RPE-and-accumulation-of-serous_fig1_303361002](https://www.researchgate.net/figure/Human-BEST1-mutations-cause-defective-fluid-transport-in-RPE-and-accumulation-of-serous_fig1_303361002)
    
34. iPS cell modeling of Best disease: insights into the pathophysiology ..., accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3542866/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3542866/)
    
35. Phenotypic and Genetic Spectrum of Autosomal Recessive Bestrophinopathy and Best Vitelliform Macular Dystrophy - PMC - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8142704/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8142704/)
    
36. Vitelliform maculopathy: Diverse etiologies originating from one common pathway - PubMed, accessed July 27, 2025, [https://pubmed.ncbi.nlm.nih.gov/36720370/](https://pubmed.ncbi.nlm.nih.gov/36720370/)
    
37. Choroidal neovascularization secondary to Best's vitelliform mac - Dove Medical Press, accessed July 27, 2025, [https://www.dovepress.com/choroidal-neovascularization-secondary-to-bestrsquos-vitelliform-macul-peer-reviewed-fulltext-article-OPTH](https://www.dovepress.com/choroidal-neovascularization-secondary-to-bestrsquos-vitelliform-macul-peer-reviewed-fulltext-article-OPTH)
    
38. Best Vitelliform Macular Dystrophy Natural History Study Report 2: Fundus Autofluorescence and Optical Coherence Tomography - PubMed, accessed July 27, 2025, [https://pubmed.ncbi.nlm.nih.gov/40086732/](https://pubmed.ncbi.nlm.nih.gov/40086732/)
    
39. Epiretinal membrane: an overview and update - PMC - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11607056/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11607056/)
    
40. Novel Quantitative Assessment of Metamorphopsia in Maculopathy - PMC - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4299468/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4299468/)
    
41. Idiopathic Macular Hole: A Comprehensive Review of Its Pathogenesis and of Advanced Studies on Metamorphopsia - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6556255/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6556255/)
    
42. Epiretinal membrane: an overview and update - PMC, accessed July 27, 2025, [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607056/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607056/)
    
43. Macular dystrophies: clinical and imaging features, molecular genetics and therapeutic options - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7147237/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7147237/)
    
44. Unraveling the Puzzle of Central Serous Chorioretinopathy: Exploring Psychological Factors and Pathophysiological Mechanisms - PMC, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10395186/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10395186/)
    
45. Association between endogenous cortisol level and the risk of central serous chorioretinopathy: a Meta-analysis - PMC, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5824087/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5824087/)
    
46. Full article: Current and emerging treatment options for central serous chorioretinopathy, accessed July 27, 2025, [https://www.tandfonline.com/doi/full/10.1080/17469899.2024.2336241](https://www.tandfonline.com/doi/full/10.1080/17469899.2024.2336241)
    
47. Unraveling the Puzzle of Central Serous Chorioretinopathy ..., accessed July 27, 2025, [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395186/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395186/)
    
48. (PDF) Charles Bonnet syndrome in adults with inherited retinal ..., accessed July 27, 2025, [https://www.researchgate.net/publication/393179033_Charles_Bonnet_syndrome_in_adults_with_inherited_retinal_disease_prevalence_and_patient_perspectives](https://www.researchgate.net/publication/393179033_Charles_Bonnet_syndrome_in_adults_with_inherited_retinal_disease_prevalence_and_patient_perspectives)
    
49. Re: Visual hallucinations (Charles Bonnet syndrome) as the presenting sign of pituitary adenoma Response | Request PDF - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/225295264_Re_Visual_hallucinations_Charles_Bonnet_syndrome_as_the_presenting_sign_of_pituitary_adenoma_Response](https://www.researchgate.net/publication/225295264_Re_Visual_hallucinations_Charles_Bonnet_syndrome_as_the_presenting_sign_of_pituitary_adenoma_Response)
    
50. complex visual hallucinations: Topics by Science.gov, accessed July 27, 2025, [https://www.science.gov/topicpages/c/complex+visual+hallucinations.html](https://www.science.gov/topicpages/c/complex+visual+hallucinations.html)
    
51. Visual Hallucinations After Intravitreal Injection of Bevacizumab in Vascular Age-related Macular Degeneration | Request PDF - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/6612539_Visual_Hallucinations_After_Intravitreal_Injection_of_Bevacizumab_in_Vascular_Age-related_Macular_Degeneration](https://www.researchgate.net/publication/6612539_Visual_Hallucinations_After_Intravitreal_Injection_of_Bevacizumab_in_Vascular_Age-related_Macular_Degeneration)
    
52. perceptual consequences of visual loss: `positive' pathologies of vision | Brain | Oxford Academic, accessed July 27, 2025, [https://academic.oup.com/brain/article/122/7/1247/329382](https://academic.oup.com/brain/article/122/7/1247/329382)
    
53. Adult-onset Foveomacular Vitelliform Dystrophy:a Teaching Case Report | The Journal of Optometric Education, accessed July 27, 2025, [https://journal.opted.org/article/adult-onset-foveomacular-vitelliform-dystrophy-a-teaching-case-report/](https://journal.opted.org/article/adult-onset-foveomacular-vitelliform-dystrophy-a-teaching-case-report/)
    
54. Tolerance of high and low amounts of PLGA microspheres loaded ..., accessed July 27, 2025, [https://www.researchgate.net/publication/319992925_Tolerance_of_high_and_low_amounts_of_PLGA_microspheres_loaded_with_mineralocorticoid_receptor_antagonist_in_retinal_target_site](https://www.researchgate.net/publication/319992925_Tolerance_of_high_and_low_amounts_of_PLGA_microspheres_loaded_with_mineralocorticoid_receptor_antagonist_in_retinal_target_site)
    
55. Persistent macular oedema following Best vitelliform macular ..., accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9091876/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9091876/)
    
56. Notice: Many of our licenses require that you print a copy of the article and delete the electronic file. Thank you. - American Optometric Association (AOA), accessed July 27, 2025, [https://www.aoa.org/assets/documents/EBO/CRG%20-%20GLAUCOMA%204/933-001ABEDI2013.pdf](https://www.aoa.org/assets/documents/EBO/CRG%20-%20GLAUCOMA%204/933-001ABEDI2013.pdf)
    
57. Choroidal Neovascularization Associated with Best Vitelliform ..., accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9169145/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9169145/)
    
58. Vascular Endothelial Growth Factor Inhibitors for Ocular Indications - Medical Clinical Policy Bulletins | Aetna, accessed July 27, 2025, [https://www.aetna.com/cpb/medical/data/700_799/0701.html](https://www.aetna.com/cpb/medical/data/700_799/0701.html)
    
59. Identifying Conversion to - Review of Optometry, accessed July 27, 2025, [https://www.reviewofoptometry.com/CMSDocuments/2022/06/ro0622i.pdf](https://www.reviewofoptometry.com/CMSDocuments/2022/06/ro0622i.pdf)
    
60. RANIBIZUMAB 0.5 MG TREATMENT IN ADOLESCENTS WITH ..., accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8219082/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8219082/)
    
61. [Best's disease--family case report] - PubMed, accessed July 27, 2025, [https://pubmed.ncbi.nlm.nih.gov/19517849/](https://pubmed.ncbi.nlm.nih.gov/19517849/)
    
62. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease - PubMed, accessed July 27, 2025, [https://pubmed.ncbi.nlm.nih.gov/14644242/](https://pubmed.ncbi.nlm.nih.gov/14644242/)
    
63. Oxidative Stress and Antioxidants in Age-Related Macular Degeneration - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10376043/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10376043/)
    
64. Age-Related Macular Degeneration | Eye Conditions | Mr Zaid Shalchi, accessed July 27, 2025, [https://zaidshalchi.co.uk/conditions/age-related-macular-degeneration-amd/](https://zaidshalchi.co.uk/conditions/age-related-macular-degeneration-amd/)
    
65. Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration | Request PDF - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/382313936_Oral_Antioxidant_and_LuteinZeaxanthin_Supplements_Slow_Geographic_Atrophy_Progression_to_the_Fovea_in_Age-Related_Macular_Degeneration](https://www.researchgate.net/publication/382313936_Oral_Antioxidant_and_LuteinZeaxanthin_Supplements_Slow_Geographic_Atrophy_Progression_to_the_Fovea_in_Age-Related_Macular_Degeneration)
    
66. Complement activation and choriocapillaris loss in early AMD: Implications for pathophysiology and therapy - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4339497/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4339497/)
    
67. Dietary modification and supplementation for the treatment of age-related macular degeneration | Request PDF - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/276156610_Dietary_modification_and_supplementation_for_the_treatment_of_age-related_macular_degeneration](https://www.researchgate.net/publication/276156610_Dietary_modification_and_supplementation_for_the_treatment_of_age-related_macular_degeneration)
    
68. Mediterranean diet and incidence of advanced AMD: The EYE-RISK CONSORTIUM | Request PDF - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/327007422_Mediterranean_diet_and_incidence_of_advanced_AMD_The_EYE-RISK_CONSORTIUM](https://www.researchgate.net/publication/327007422_Mediterranean_diet_and_incidence_of_advanced_AMD_The_EYE-RISK_CONSORTIUM)
    
69. Genetic studies of Age-related macular degeneration: lessons, challenges and opportunities for disease management - PMC - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3514599/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3514599/)
    
70. Implications of Fatty Acids for Age-Related Macular Degeneration: Evidence and Recommendations - PMC - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12190884/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12190884/)
    
71. Patterned macular dystrophy 1 - Genopedia, accessed July 27, 2025, [https://genopedia.com/condition/Patterned%20macular%20dystrophy%201](https://genopedia.com/condition/Patterned%20macular%20dystrophy%201)
    
72. Nature and nurture- genes and environment- predict onset and progression of macular degeneration - PMC - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6446565/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6446565/)
    
73. A Blue-Blocking Intraocular Lens Should Be Used in Cataract Surgery - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/7913115_A_Blue-Blocking_Intraocular_Lens_Should_Be_Used_in_Cataract_Surgery](https://www.researchgate.net/publication/7913115_A_Blue-Blocking_Intraocular_Lens_Should_Be_Used_in_Cataract_Surgery)
    
74. Pathophysiology of Age-Related Macular Degeneration ..., accessed July 27, 2025, [https://d-nb.info/1275580645/34](https://d-nb.info/1275580645/34)
    
75. Canine Best disease as a translational model - PMC - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11794707/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11794707/)
    
76. Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7708583/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7708583/)
    
77. Research Technique: Near-infrared excited Reduced-illuminance Autofluorescence Imaging | Center for Hereditary Retinal Degenerations (CHRD) | Perelman School of Medicine at the University of Pennsylvania, accessed July 27, 2025, [https://www.med.upenn.edu/chrd/nirrafi.html](https://www.med.upenn.edu/chrd/nirrafi.html)
    
78. Impaired Bestrophin Channel Activity in an iPSC-RPE Model of Best Vitelliform Macular Dystrophy (BVMD) from an Early Onset Patient Carrying the P77S Dominant Mutation - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/361793427_Impaired_Bestrophin_Channel_Activity_in_an_iPSC-RPE_Model_of_Best_Vitelliform_Macular_Dystrophy_BVMD_from_an_Early_Onset_Patient_Carrying_the_P77S_Dominant_Mutation](https://www.researchgate.net/publication/361793427_Impaired_Bestrophin_Channel_Activity_in_an_iPSC-RPE_Model_of_Best_Vitelliform_Macular_Dystrophy_BVMD_from_an_Early_Onset_Patient_Carrying_the_P77S_Dominant_Mutation)
    
79. opht-20201231 - SEC.gov, accessed July 27, 2025, [https://www.sec.gov/Archives/edgar/data/1410939/000141093921000007/opht-20201231.htm](https://www.sec.gov/Archives/edgar/data/1410939/000141093921000007/opht-20201231.htm)
    
80. Small Molecules Restore Bestrophin 1 Expression and Function of Both Dominant and Recessive Bestrophinopathies in Patient-Derived Retinal Pigment Epithelium, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7405785/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7405785/)
    
81. Gene therapy: The future is now - Optometry Times, accessed July 27, 2025, [https://www.optometrytimes.com/view/gene-therapy-future-now](https://www.optometrytimes.com/view/gene-therapy-future-now)
    
82. Debate on innovation in the field of rare retinal disease - UK Parliament, accessed July 27, 2025, [https://researchbriefings.files.parliament.uk/documents/CDP-2025-0015/CDP-2025-0015.pdf](https://researchbriefings.files.parliament.uk/documents/CDP-2025-0015/CDP-2025-0015.pdf)
    
83. Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7414644/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7414644/)
    
84. Stem cell therapy for macular degeneration - Wikipedia, accessed July 27, 2025, [https://en.wikipedia.org/wiki/Stem_cell_therapy_for_macular_degeneration](https://en.wikipedia.org/wiki/Stem_cell_therapy_for_macular_degeneration)
    
85. Stem cells in retinal regeneration: past, present and future - Company of Biologists Journals, accessed July 27, 2025, [https://journals.biologists.com/dev/article/140/12/2576/45753/Stem-cells-in-retinal-regeneration-past-present](https://journals.biologists.com/dev/article/140/12/2576/45753/Stem-cells-in-retinal-regeneration-past-present)
    
86. Pluripotent stem cell therapy for retinal diseases - Ahmed - Annals of Translational Medicine, accessed July 27, 2025, [https://atm.amegroups.org/article/view/61496/html](https://atm.amegroups.org/article/view/61496/html)
    
87. Stem cell-derived retinal pigment epithelium cell therapy: Past and future directions - Frontiers, accessed July 27, 2025, [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1098406/full](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1098406/full)
    
88. Simulating prosthetic vision: I. Visual models of phosphenes | Request PDF - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/26274487_Simulating_prosthetic_vision_I_Visual_models_of_phosphenes](https://www.researchgate.net/publication/26274487_Simulating_prosthetic_vision_I_Visual_models_of_phosphenes)
    
89. An update on retinal prostheses - PMC - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7198351/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7198351/)
    
90. Gene-agnostic approaches to treating inherited retinal degenerations - PMC, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10133473/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10133473/)
    
91. vision glare sensitivity: Topics by Science.gov, accessed July 27, 2025, [https://www.science.gov/topicpages/v/vision+glare+sensitivity](https://www.science.gov/topicpages/v/vision+glare+sensitivity)
    
92. (PDF) Improving visual function through concomitant use of perceptual learning and brain stimulation : the case of macular degeneration - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/345990193_Improving_visual_function_through_concomitant_use_of_perceptual_learning_and_brain_stimulation_the_case_of_macular_degeneration](https://www.researchgate.net/publication/345990193_Improving_visual_function_through_concomitant_use_of_perceptual_learning_and_brain_stimulation_the_case_of_macular_degeneration)
    
93. 20 Best VS Code Themes in 2025 | Jit - Jit.io, accessed July 27, 2025, [https://www.jit.io/blog/best-vs-code-themes-2023](https://www.jit.io/blog/best-vs-code-themes-2023)
    
94. 10 Best Code Editors with Accessibility Features - Daily.dev, accessed July 27, 2025, [https://daily.dev/blog/10-best-code-editors-with-accessibility-features](https://daily.dev/blog/10-best-code-editors-with-accessibility-features)
    
95. 19 Best VSCode Themes to Boost Your Coding Experience (2025) - Snappify, accessed July 27, 2025, [https://snappify.com/blog/best-vscode-themes](https://snappify.com/blog/best-vscode-themes)
    
96. 23 Best VS Code Themes in 2024 - DEV Community, accessed July 27, 2025, [https://dev.to/ikoichi/23-best-vs-code-themes-in-2024-45g1](https://dev.to/ikoichi/23-best-vs-code-themes-in-2024-45g1)
    
97. What color scheme works best for coding in daylight : r/IntelliJIDEA - Reddit, accessed July 27, 2025, [https://www.reddit.com/r/IntelliJIDEA/comments/vo6sng/what_color_scheme_works_best_for_coding_in/](https://www.reddit.com/r/IntelliJIDEA/comments/vo6sng/what_color_scheme_works_best_for_coding_in/)
    
98. Accessibility | IntelliJ IDEA Documentation - JetBrains, accessed July 27, 2025, [https://www.jetbrains.com/help/idea/accessibility.html](https://www.jetbrains.com/help/idea/accessibility.html)
    
99. Atkinson Hyperlegible Font - Braille Institute, accessed July 27, 2025, [https://www.brailleinstitute.org/freefont/](https://www.brailleinstitute.org/freefont/)
    
100. Font Legibility for Students who are Blind or Visually Impaired, accessed July 27, 2025, [https://www.teachingvisuallyimpaired.com/font-legibility.html](https://www.teachingvisuallyimpaired.com/font-legibility.html)
    
101. What are the Best Fonts for Accessibility? - Recite Me, accessed July 27, 2025, [https://reciteme.com/us/news/best-fonts-for-accessibility/](https://reciteme.com/us/news/best-fonts-for-accessibility/)
    
102. How to Change Font in VSCode for Comfort - TMS Outsource, accessed July 27, 2025, [https://tms-outsource.com/blog/posts/how-to-change-font-in-vscode/](https://tms-outsource.com/blog/posts/how-to-change-font-in-vscode/)
    
103. 2021 Course: 03 ICT FOR COMMUNICATION, COLLABORATION AND SUPPORT - cemca, accessed July 27, 2025, [https://www.cemca.org/ckfinder/userfiles/files/Course-%2003%20ICT%20FOR%20COMMUNICATION,%20COLLABORATION%20AND%20SUPPORT.pdf](https://www.cemca.org/ckfinder/userfiles/files/Course-%2003%20ICT%20FOR%20COMMUNICATION,%20COLLABORATION%20AND%20SUPPORT.pdf)
    
104. JAWS® – Freedom Scientific, accessed July 27, 2025, [https://www.freedomscientific.com/products/software/jaws/](https://www.freedomscientific.com/products/software/jaws/)
    
105. Assistive Technology - Visual Impairment | Florida Atlantic University, accessed July 27, 2025, [https://www.fau.edu/sas/technology/visual/](https://www.fau.edu/sas/technology/visual/)
    
106. Accessibility - SmartWiki, accessed July 27, 2025, [https://wiki.smartsimple.com/wiki/Accessibility](https://wiki.smartsimple.com/wiki/Accessibility)
    
107. Expert Guide: Writing HTML for Screen Reader Users - The A11Y Collective, accessed July 27, 2025, [https://www.a11y-collective.com/blog/html-screen-reader/](https://www.a11y-collective.com/blog/html-screen-reader/)
    
108. Semantics to Screen Readers - A List Apart, accessed July 27, 2025, [https://alistapart.com/article/semantics-to-screen-readers/](https://alistapart.com/article/semantics-to-screen-readers/)
    
109. Fusion SuiteTM - Freedom Scientific, accessed July 27, 2025, [https://www.freedomscientific.com/products/software/fusion/](https://www.freedomscientific.com/products/software/fusion/)
    
110. Talon talon-voice very simple hello world - GitHub Gist, accessed July 27, 2025, [https://gist.github.com/573/49bde937d827083a5eb7cd6d6d6eed66](https://gist.github.com/573/49bde937d827083a5eb7cd6d6d6eed66)
    
111. talonhub/community: Voice command set for Talon ... - GitHub, accessed July 27, 2025, [https://github.com/talonhub/community](https://github.com/talonhub/community)
    
112. AndreasArvidsson/andreas-talon: User scripts for Talon Voice - GitHub, accessed July 27, 2025, [https://github.com/AndreasArvidsson/andreas-talon](https://github.com/AndreasArvidsson/andreas-talon)
    
113. John Cooper jcooper-korg - GitHub, accessed July 27, 2025, [https://github.com/jcooper-korg](https://github.com/jcooper-korg)
    
114. talonvoice · GitHub Topics, accessed July 27, 2025, [https://github.com/topics/talonvoice](https://github.com/topics/talonvoice)
    
115. C-Loftus/talon-ai-tools: Query LLMs and AI tools with voice commands - GitHub, accessed July 27, 2025, [https://github.com/C-Loftus/talon-ai-tools](https://github.com/C-Loftus/talon-ai-tools)
    
116. BR Accessibility. - Bionic Reading, accessed July 27, 2025, [https://bionic-reading.com/br-accessibility/](https://bionic-reading.com/br-accessibility/)
    
117. Accessible Reading for Wordpress - Common Ninja, accessed July 27, 2025, [https://discover.commoninja.com/wordpress/plugin/accessible-reading](https://discover.commoninja.com/wordpress/plugin/accessible-reading)
    
118. Plugins - Obsidian, accessed July 27, 2025, [https://obsidian.md/plugins?search=live](https://obsidian.md/plugins?search=live)
    
119. Chrome Bionic Reader | Бионическое чтение - Chrome Web Store, accessed July 27, 2025, [https://chromewebstore.google.com/detail/chrome-bionic-reader-%D0%B1%D0%B8%D0%BE%D0%BD/bofckkbophijgakfoeihfmnjfphcabhi](https://chromewebstore.google.com/detail/chrome-bionic-reader-%D0%B1%D0%B8%D0%BE%D0%BD/bofckkbophijgakfoeihfmnjfphcabhi)
    
120. New Metamorphopsia Tool Opens Potential Treatment Avenue, accessed July 27, 2025, [https://www.reviewofoptometry.com/news/article/new-metamorphopsia-tool-opens-potential-treatment-avenue](https://www.reviewofoptometry.com/news/article/new-metamorphopsia-tool-opens-potential-treatment-avenue)
    
121. Genetic Basis of Inherited Retinal Disease in a Molecularly Characterized Cohort of More Than 3000 Families from the United Kingdom - PubMed Central, accessed July 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7520514/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7520514/)
    
122. Eye2Gene: prediction of causal inherited retinal disease gene from multimodal imaging using deep-learning - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/364725353_Eye2Gene_prediction_of_causal_inherited_retinal_disease_gene_from_multimodal_imaging_using_deep-learning](https://www.researchgate.net/publication/364725353_Eye2Gene_prediction_of_causal_inherited_retinal_disease_gene_from_multimodal_imaging_using_deep-learning)
    
123. Teprotumumab (Tepezza, Amgen) receives marketing authorisation from MHRA, accessed July 27, 2025, [https://europe.ophthalmologytimes.com/view/tepezza-receives-marketing-authorisation-from-mhra](https://europe.ophthalmologytimes.com/view/tepezza-receives-marketing-authorisation-from-mhra)
    
124. Diagnostic yield for patients within a given age range within this study - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/figure/Diagnostic-yield-for-patients-within-a-given-age-range-within-this-study_fig1_350285993](https://www.researchgate.net/figure/Diagnostic-yield-for-patients-within-a-given-age-range-within-this-study_fig1_350285993)
    
125. (PDF) Autosomal Recessive Bestrophinopathy: Clinical Features, Natural History, and Genetic Findings in Preparation for Clinical Trials - ResearchGate, accessed July 27, 2025, [https://www.researchgate.net/publication/344612202_Autosomal_Recessive_Bestrophinopathy_Clinical_Features_Natural_History_and_Genetic_Findings_in_Preparation_for_Clinical_Trials](https://www.researchgate.net/publication/344612202_Autosomal_Recessive_Bestrophinopathy_Clinical_Features_Natural_History_and_Genetic_Findings_in_Preparation_for_Clinical_Trials)
    
126. Typical Best vitelliform dystrophy secondary to biallelic variants in BEST1 Authors - UCL Discovery, accessed July 27, 2025, [https://discovery.ucl.ac.uk/10167009/2/Michaelides_Final%20manuscript%20Re%20submission%20BEST1%2019.2.2023.pdf](https://discovery.ucl.ac.uk/10167009/2/Michaelides_Final%20manuscript%20Re%20submission%20BEST1%2019.2.2023.pdf)
    

**